The Priority Review

Tag

ESA

1 story

Stories

  1. Clinical trials

    Kind Pharmaceuticals registers Phase 3 study of AND017 in NDD-CKD anemia

    The study, led by Kind Pharmaceuticals LLC, plans to enroll 240 participants and begin in February 2027. It compares AND017 capsules with erythropoietin stimulating agents in non-dialysis-dependent chronic kidney disease patients with anemia.